Revolution Medicines wins CHMP backing for Rasonque in metastatic pancreatic cancer

On October 15, 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending European Union marketing authorisation for Rasonque (daraxonrasib), a once-daily oral RAS(ON) inhibitor, as monotherapy for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. The recommendation, announced by Revolution Medicines, Inc. (Nasdaq: RVMD) of Redwood City, California, concerns a form of cancer that has resisted most treatment advances for decades. Reuters reported on October 15 that the committee had recommended EU approval of the drug, potentially offering patients in the bloc a new option for a disease with limited effective therapies.

Pancreatic cancer is among the deadliest tumours. Approximately 147,000 people are diagnosed with pancreatic cancer in Europe each year, and the five-year survival rate remains below 10 percent. Roughly 80 percent of patients are diagnosed only after the disease has spread, and chemotherapy remains the primary treatment once it does. For adults with metastatic pancreatic adenocarcinoma whose disease has worsened after prior treatment, options are few and the prognosis is poor. The European Medicines Agency noted on October 15 that standard-of-care chemotherapy in this setting offers limited efficacy and substantial toxicity, leaving what it described as a clear need for better treatment options.

Rasonque, chemically known as daraxonrasib, works by blocking RAS proteins that can drive cancer-cell growth. In pancreatic adenocarcinoma, mutations in the RAS gene cause these proteins to be permanently switched on, leading to uncontrolled growth of cancer cells. Daraxonrasib binds to cyclophilin A to form a complex that attaches to RAS proteins, blocking their activity and slowing cancer growth. The medicine is an oral, RAS(ON) multi-selective, noncovalent, tri-complex inhibitor, taken once daily as a tablet.

The positive opinion now goes to the European Commission, which will make the final call and is expected to fast-track the EU-wide decision. If granted, the centralised authorization would apply across all EU member states, as well as Iceland, Norway and Liechtenstein. The recommendation follows an expedited, phased review conducted under the EMA's Cancer Medicines Pathfinder project, which identified Rasonque as a high-priority medicine addressing an unmet need in this patient group. The review started in early July 2026.

Key Facts

The CHMP opinion recommends marketing authorization for daraxonrasib as monotherapy for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. OncLive reported on October 15 that the opinion was supported by the phase 3 RASolute 302 trial, registered as NCT06625320. In that global randomised study, daraxonrasib was compared with an investigator's choice of cytotoxic chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma. The trial enrolled about 500 patients, of whom 92 percent had a confirmed RAS G12 mutation.

The survival data were striking. In the intent-to-treat population, daraxonrasib (n=248) produced a median overall survival of 13.2 months, compared with 6.7 months for chemotherapy (n=252), with a hazard ratio of 0.40 (95 percent CI, 0.30-0.53; P=4.6 x 10^-11). Revolution Medicines said on October 15 that the result represented a 60 percent reduction in the risk of death compared with chemotherapy. Median progression-free survival by blinded independent central review was 7.2 months versus 3.6 months (HR, 0.49; 95 percent CI, 0.38-0.64). An ad hoc overall survival analysis showed a median of 12.4 months versus 6.7 months (HR, 0.49; 95 percent CI, 0.39-0.62). The company said the trial met all primary and key secondary endpoints in both the RAS G12 mutant population and the overall intent-to-treat population.

The regulatory path was unusually fast. The European Medicines Agency said on October 15 that its phased review evaluated quality, non-clinical and clinical data in stages, shortening the assessment time to less than 150 days, compared with a standard evaluation that can take up to 210 active days and usually around a year overall. Rasonque also holds orphan medicinal product designation for pancreatic cancer in the EU. In the United States, the Food and Drug Administration approved the drug on August 26, 2026, and it is priced at $39,800 for a 30-day supply.

The most common side effects in the study were diarrhea, rash, stomatitis, nausea and vomiting. The primary analysis of RASolute 302 was presented at the 2026 ASCO Annual Meeting and published in The New England Journal of Medicine. In the United States, strong demand after those results prompted the FDA to grant access through its compassionate use program for patients with serious or life-threatening illnesses.

Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, said in a statement that the positive opinion marks a major step toward making Rasonque available to eligible adults with metastatic pancreatic cancer in the European Union. He said the expedited review under the EMA's Cancer Medicines Pathfinder project highlights how innovative regulatory pathways may help bring promising medicines to patients sooner. Goldsmith added that the company looks forward to the European Commission's decision as it continues to work with regulatory authorities around the world to pursue additional approvals and broaden access to Rasonque.

Analysis

The bigger picture here is that a positive CHMP opinion is not the same thing as a European launch, but it is the point at which the clinical and commercial logic of a medicine becomes very hard to reverse. For Revolution Medicines, the recommendation turns an American approval into a credible route into a second major market. For European oncologists, it creates the prospect of the first broad RAS-targeted option for a patient group that has had little new to offer for years. The judgement worth making explicit is about the size of the benefit rather than the paperwork: a hazard ratio of 0.40 and a 60 percent reduction in the risk of death are not marginal gains over chemotherapy, and the CHMP does not attach its name to marginal gains in a disease this severe.

The enthusiasm nevertheless deserves calibration. Alok Khorana, MD, of Cleveland Clinic, told OncLive that the development 'signals a new era in gastrointestinal oncology' but cautioned that 'this is not a magic bullet. It's not a cure. Nobody with advanced pancreatic cancer is cured by this drug.' He pointed to emerging resistance through non-KRAS G12C pathways and secondary RAS mutations. That resistance is the unresolved question at the centre of the Rasonque story, because a drug that buys months rather than years invites the next question almost immediately. A second generation of RAS inhibitors is already on the way with less toxicity in early trials, which suggests Rasonque may be the opening chapter rather than the final word.

What this really means is that the regulatory and the scientific clocks are now running at different speeds. European regulators have compressed an assessment that can take up to 210 active days into less than 150 days, and the European Commission is expected to fast-track its decision. Science, by contrast, moves at the pace of resistance mechanisms and confirmatory data. The trial data also carry a structural caveat that will shape the European label debate: 92 percent of enrolled patients had a confirmed RAS G12 mutation, even though the trial set out to test the drug in the overall intent-to-treat population, where the benefit was still statistically robust. How broadly the European label is written will therefore determine whether Rasonque reaches the full metastatic pancreatic cancer population or a genetically defined subset of it.

Money is the third thread. The US price of $39,800 for a 30-day supply is a benchmark European payers will study closely, and health technology assessment bodies across the bloc will weigh a median survival gain of roughly 6.5 months against that figure. The unmet need is extreme, but access is not automatic.

Why It Matters

Pancreatic cancer's five-year survival rate has remained below 10 percent for decades, and roughly 80 percent of patients learn they have the disease only after it has spread. Against that backdrop, a therapy that extends median overall survival from 6.7 months to 13.2 months in previously treated metastatic disease changes what the diagnosis means for that specific group. With approximately 147,000 people diagnosed with pancreatic cancer in Europe each year, even a modestly effective new option would touch tens of thousands of families annually, and this one is not modest in trial terms.

The decision also matters as a test of European regulatory reform. Rasonque was identified under the EMA's Cancer Medicines Pathfinder project as a high-priority medicine, and its phased review shortened the assessment to less than 150 days. If the European Commission follows the CHMP recommendation quickly, the episode becomes evidence that the pathway delivers real speed rather than procedural promise. If it stalls, the credibility of the expedited route suffers alongside the drug.

For Revolution Medicines (Nasdaq: RVMD), the opinion is a second commercial engine behind the US launch. FDA approval on August 26, 2026 was followed by demand strong enough to push the agency toward compassionate use access, and a European authorisation would extend that demand to a region with a high incidence of pancreatic cancer and a largely chemotherapy-only standard of care.

Next Up

The European Commission will now consider the recommendation and is expected to fast-track the EU-wide decision. Once granted, the authorization is valid in all EU member states plus the EEA countries Iceland, Norway and Liechtenstein. Goldsmith said the company continues to work with regulatory authorities around the world to pursue additional approvals and broaden access to Rasonque, so further filings should be expected.

Beyond the immediate decision, attention shifts to confirmatory survival data, to pricing talks with European payers, and to the second generation of RAS inhibitors now in early trials with a less toxic profile. Whether Rasonque becomes a durable standard or a first step will depend on how quickly resistance biology catches up with it.